TENX — Tenax Therapeutics, Inc.
$1.72+4.88%
Last close: · regular session
After-hours $1.73 +0.52% ·
Last 60 sessions
TENX closed at $1.72 (+4.88%) on Oct 27, 2026. Active shelf registration (S-3, Mar 2026). Float: 4.5M shares. Latest SEC filing: 8-K on Oct 8, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for TENX in the TickerWise workspace.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 4
- Website: https://www.tenaxthera.com
Latest SEC filings for TENX
Latest TENX news
- TENX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Tenax Therapeutics, Inc. Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.